Skip to main content
Vitaflo VIA Education Portal
  • PHENYLKETONURIA - INFANTS
  • PHENYLKETONURIA - CHILDREN
  • PHENYLKETONURIA - ADOLESCENTS AND ADULTS
  • PHENYLKETONURIA - MATERNAL
  • PHENYLKETONURIA - GMP
  • RARE DISORDERS OF PROTEIN METABOLISM
  • LIPID DISORDERS
  • GLYCOGEN STORAGE DISEASE
  • DRUG RESISTANT EPILEPSY - KETOGENIC DIET
  • DRUG RESISTANT EPILEPSY - K.VITA
  • KIDNEY DISEASE - PAEDIATRIC
  • KIDNEY DISEASE – ADULTS
  • NUTRITION SUPPORT
  • MULTILINGUAL RESOURCES
  • Product calculators and tools
  • CPD REFLECTION TOOL
  • K.VITA CALCULATOR
  • MCT CALCULATOR - LIPID DISORDERS
  • PKU TRIO CALCULATOR
  • KETOGENIC DIET NUTRITIONAL INTAKE TOOL
  • MPKU & LACTATION INTAKE ASSESSMENT
EVENTS
COURSES
BLOGS
Register Login
Source: https://www.vitaflo-via.com/disorder-resources/pku-gmp/pku-spheretm-managing-phe-control-case-study

Breadcrumb

  1. Home

PKU sphere™: Managing Phe Control | Case Study

Want to access this resource?

REGISTER NOW LOGIN

Description

A case study introducing PKU sphere™ in an 8 year old female with a low Phenylalanine (Phe) tolerance and managing Phe control.

Notes:

PKU sphere is a Food for Special Medical Purposes

  • Weight: 24kg (25th percentile)
  • Height: 125cm (25th percentile)

Protein Equivalent (PE) from Amino Acid (AA) - based protein substitute: 60g/day (3 x 20g PE)

Natural protein intake: 4g/day

Total protein intake: 2.7g/kg/day

Target phenylalanine (Phe) range: 120-360μmol/L


Background

An 8-year-old girl taking conventional AA based protein substitute three times a day expressed an interest in taking a new Glycomacropeptide (GMP) - based protein substitute after tasting it in the PKU clinic. The median blood Phe concentration for her previous 12 months was 245 µmol/L with 76% of her blood spot Phe levels within the recommended target range for age. This was considered good control. Her growth, both weight and height were on the 25th centile, with an appropriate body mass index. She ate a limited variety of foods (low protein bread, potato products, salad and low protein biscuits only) despite many attempts to try to expand the variety of foods eaten in her diet. She was taking 60g/day PE from 3 x 20g PE AA based protein substitutes (2.5g protein/kg) and 4g/day of natural protein (200 mg/day Phe).

The guidelines for the introduction of PKU sphere in section 2.5 of the ‘Practical guide for PKU sphere’ were followed. No adjustment or reduction of Phe exchanges was required.

Stage 1

  1. One sachet of PKU sphere20 replaces one AA based protein substitute
  2. Continue taking 2 x AA based protein substitutes
  3. Weekly fasting capillary blood spots
  4. Growth monitored frequently

Table 1

Introduction of 1 x PKU sphere20 (20g PE) in addition to 2 x AA based protein substitutes (40g PE)

Week Phe µmol/L  Tyr µmol/L
1 240 40
2 190 50
3 120 40
4 280 50

No difficulties were observed and the new product was taken well. Weight stable.

After 4 weeks of introducing one sachet of PKU sphere20, blood Phe concentration remained within target reference range.

Therefore, PKU sphere20 increased to 2 sachets per day with 1 x AA based protein substitute.

  1. Two sachets of PKU sphere20 replace 2 x AA based protein substitutes
  2. Continue taking 1 x 20g PE of AA based protein substitute
  3. Weekly fasting capillary blood spots
  4. Growth monitored frequently
  5. Review after 4 weeks and change to all PKU sphere20 providing Phe levels are consistently below the target reference range

Table 2

Introduction of 2 x PKU sphere20 (40g PE) in addition to 1 x AA based protein substitute (20g PE).

Week Phe µmol/L Tyr µmol/L
1 260 30
2 400 50
3 120 40
4 580 50

No illness. Reported taking all protein substitute. Weight stable.

Comments

There appeared to be no obvious reason for the increase in the blood Phe concentration. The patient had no illness and appeared to be adherent with her diet. However, her parents noticed she was reluctant to finish all her AA based protein substitute making total protein substitute intake less consistent than usual. A home visit established a few potential causes:

  1. It was holiday time and the familiar daily routine of taking protein substitute was changed. Each morning she had a ‘lie in’ in bed therefore took the protein substitute later in the mornings.
  2. Intake of food was less regular and Phe exchanges had not been measured accurately when eating outside the home.
  3. She had attended a ‘sleep-over’ on two occasions and delayed taking her protein substitute till later in the morning.

Plan

As it appeared the fluctuating Phe control may have been either due to inadequate protein substitute intake or extra natural protein intake when eating out, it was agreed to repeat stage 2 and review after 4 weeks.

Table 3

Continuation of 2 x PKU sphere20 (40g PE) in addition to 1 x L-AA supplement (20g PE)

Week Phe µmol/L Tyr µmol/L
9 270 40
10 130 50
11 190 40
12 260 50

Routine established. Weight stable.

Once her usual routine returned and she was back in school, the Phe concentrations returned to the patient’s usual high standards. She was able to change to 3 sachets daily of PKU sphere20 after 8 weeks of following 2 sachets of PKU sphere20 and 1 pouch of AA PS.

  1. Increase to three sachets of PKU sphere20
  2. Stop AA protein substitute
  3. Weekly fasting capillary blood spots
  4. Growth monitored frequently

Table 4.

Increase to 3 x PKU sphere20 (60g PE)

Week Phe µmol/L Tyr µmol/L
13 180 40
14 220 50
15 190 40
16 240 40

No illness. Reported taking all protein substitute. Weight stable.

This young girl continued to have regular assessment of blood concentrations and she demonstrated good control of both Phe and Tyrosine concentrations (see Table 4.). Her growth continued to follow the 25th percentile for both height and weight and she continued to do well with her GMP-based protein substitute; PKU sphere20.

  1. Transitioning to any new protein substitute needs regular monitoring.
  2. If Phe control deteriorates it is important to consider changes to daily routine, in addition to other common causes of poor Phe control.
  3. Using a methodical method of introducing a new dietary change provides confidence to the family and allows identification of the cause and the solution if any problems arise.
DOWNLOAD

Author

  • Anne Daly

    Birmingham Children's Hospital, UK

Published

  • 01/11/2018

TAGS

PKU & GMP

OTHER RESOURCES YOU MAY BE INTERESTED IN

healthcare professional looking at a slide in a microsope
Fallstudie

Erkenntnisse aus der größten umfassenden Langzeitstudie mit PKU sphere® bei Kindern und Jugendlichen 1-4

27/01/2026
stack of books
Evidence Summary

The effects of cGMP on general health status in children with PKU

09/12/2025
Man opening a book with light spilling out of it
Event Recording

Highlights from the Element clinical trial and practical take aways for GMP use in PKU

21/11/2025

WE HAVE A WEALTH OF RESOURCES FOR

pku-infant.svg
pku-infant-white.svg

PKU - Infants

pku-children.svg
pku-children-white.svg

PKU - Children

pku-adolescents-adults.svg
pku-adolescents-adults-white.svg

PKU - Adolescents and Adults

mpku.svg
mpku-white.svg

Maternal PKU

pku-gmp.svg
pku-gmp-white.svg

PKU & GMP

Rare disorders
rare-disorders-white.svg

Rare Disorders of Protein Metabolism

Lipid disorder
Lipid disorder white

Lipid Disorders

gsd.svg
GDS white

Glycogen Storage Disease

Ketogenic diet
Ketogenic diet white

Drug Resistant Epilepsy - Ketogenic Diet

k-vita-icon.svg
k-vita-icon-white.svg

Drug Resistant Epilepsy - K.Vita

kidney-disease-child.svg
kidney-disease-child-white.svg

Kidney Disease - Paediatric

kidney-disease-adult.svg
kidney-disease-adult-white.svg

Kidney Disease – Adults

Nutrican support
Nutrican support white

Nutrition Support

PKU sphere™: Managing Phe Control | Case Study
  • DISORDER AREAS
  • Phenylketonuria - Infants
  • Phenylketonuria - Children
  • Phenylketonuria - Adolescents and Adults
  • Phenylketonuria - Maternal
  • Phenylketonuria - GMP
  • Rare Disorders of Protein Metabolism
  • Lipid Disorders
  • Glycogen Storage Disease
  • Drug Resistant Epilepsy - Ketogenic Diet
  • Drug Resistant Epilepsy - K.Vita
  • Kidney Disease - Paediatric
  • Kidney Disease - Adults
  • Nutrition Support
  • Multilingual Resources
  • TOOLS
  • CPD Reflection Tool
  • K.Vita Calculator
  • MCT Calculator
  • PKU Trio Calculator
  • mPKU & Lactation Intake Assessment
  • BLOG
  • Blogs
  • CONTACT
  • Contact Us
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Accessibility Statement
  • Follow us on LinkedIn
Vitaflo - Enhancing Lives Together

Vitaflo International Ltd, Suite1.11, South Harrington Building, 182 Sefton Street, Brunswick Business Park, Liverpool L3 4BQ, UK

©2026 Vitaflo International Limited

® Reg. Trademarks of Societe des Produits Nestle S.A © 2025 All rights reserved Societe des Produits Nestle S.A, Vevey, Switzerland